.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Update on Use of Immunotherapy in Hematologic Malignancies

EP. 1: Immunotherapy in Hematologic Malignancies

June 24th 2015

EP. 2: Responses With Immunotherapy Versus Chemotherapy

June 24th 2015

EP. 3: Immunotherapy-Related Adverse Events

June 24th 2015

EP. 4: Rituximab, Obinutuzumab, and Ofatumumab in CLL

June 24th 2015

EP. 5: Blinatumomab in Philadelphia Chromosome-Negative ALL

June 24th 2015

EP. 6: Measuring Response to Novel Therapies in ALL

June 24th 2015

EP. 7: Elotuzumab in Relapsed/Refractory Multiple Myeloma

June 24th 2015

EP. 8: Daratumumab, Vaccines in Multiple Myeloma

June 24th 2015

EP. 9: Treatment Advancements in Lymphoma

June 24th 2015

EP. 10: PD-1 Inhibition in Hodgkin's Lymphoma

June 24th 2015

EP. 11: Future Immunotherapies for Hematologic Malignancies

June 24th 2015